HK1180327A1 - Thioacetate compounds, compositions and methods of use - Google Patents

Thioacetate compounds, compositions and methods of use

Info

Publication number
HK1180327A1
HK1180327A1 HK13107640.4A HK13107640A HK1180327A1 HK 1180327 A1 HK1180327 A1 HK 1180327A1 HK 13107640 A HK13107640 A HK 13107640A HK 1180327 A1 HK1180327 A1 HK 1180327A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
thioacetate compounds
thioacetate
compounds
Prior art date
Application number
HK13107640.4A
Other languages
English (en)
Inventor
Samedy Ouk
Esmir Gunic
Jean-Michel Vernier
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1180327(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of HK1180327A1 publication Critical patent/HK1180327A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
HK13107640.4A 2010-06-16 2013-06-28 Thioacetate compounds, compositions and methods of use HK1180327A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35549110P 2010-06-16 2010-06-16
PCT/US2011/040585 WO2011159839A2 (fr) 2010-06-16 2011-06-15 Composés de thioacétate, compositions et procédés d'utilisation

Publications (1)

Publication Number Publication Date
HK1180327A1 true HK1180327A1 (en) 2013-10-18

Family

ID=45348850

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13107640.4A HK1180327A1 (en) 2010-06-16 2013-06-28 Thioacetate compounds, compositions and methods of use
HK16107170.9A HK1219102A1 (zh) 2010-06-16 2016-06-21 硫代乙酸鹽化合物，組合物和其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16107170.9A HK1219102A1 (zh) 2010-06-16 2016-06-21 硫代乙酸鹽化合物，組合物和其使用方法

Country Status (41)

Country Link
US (5) US10266493B2 (fr)
EP (5) EP2712861B1 (fr)
JP (5) JP5551310B2 (fr)
KR (2) KR101608604B1 (fr)
CN (2) CN103068801B (fr)
AR (1) AR081930A1 (fr)
AU (1) AU2011268360B2 (fr)
BR (1) BR112012032028B1 (fr)
CA (1) CA2802535C (fr)
CL (1) CL2012003546A1 (fr)
CO (1) CO6640311A2 (fr)
CR (1) CR20120649A (fr)
CU (1) CU24126B1 (fr)
CY (1) CY1120337T1 (fr)
DK (3) DK2712861T3 (fr)
DO (1) DOP2012000314A (fr)
EA (1) EA022933B1 (fr)
EC (1) ECSP12012353A (fr)
ES (3) ES2673426T3 (fr)
GT (1) GT201200339A (fr)
HK (2) HK1180327A1 (fr)
HN (1) HN2012002664A (fr)
HR (3) HRP20140391T1 (fr)
HU (2) HUE025962T2 (fr)
IL (2) IL223435A (fr)
LT (1) LT2975025T (fr)
ME (2) ME02302B (fr)
MX (2) MX2012014863A (fr)
MY (1) MY153039A (fr)
PE (1) PE20131047A1 (fr)
PL (3) PL2975025T3 (fr)
PT (3) PT2975025T (fr)
RS (3) RS57363B1 (fr)
SG (2) SG186298A1 (fr)
SI (3) SI2585437T1 (fr)
SM (2) SMT201400055B (fr)
TR (1) TR201808344T4 (fr)
TW (2) TWI501949B (fr)
UA (1) UA107115C2 (fr)
WO (1) WO2011159839A2 (fr)
ZA (1) ZA201209574B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802692C (fr) 2010-06-16 2016-01-05 Ardea Biosciences, Inc. Phenylthioacetates utiles en tant qu'agents uricosuriques
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
JP6025853B2 (ja) * 2011-11-03 2016-11-16 アルデア バイオサイエンシーズ インク． ３，４−二置換ピリジン化合物、その使用方法、および、該化合物を含む組成物
WO2014077285A1 (fr) 2012-11-14 2014-05-22 帝人ファーマ株式会社 Dérivé de pyridine
MX362747B (es) * 2013-05-13 2019-02-05 Shanghai hengrui pharmaceutical co ltd Derivado de ácido cicloalquilo, método de preparación del mismo, y aplicación farmacéutica del mismo.
WO2014209034A1 (fr) * 2013-06-27 2014-12-31 Lg Life Sciences Ltd. Dérivés de biaryle en tant qu'agonistes de gpr120
CN106458998A (zh) 2014-05-13 2017-02-22 帝人制药株式会社 吡嗪衍生物
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
CN107567443B (zh) * 2014-12-24 2023-04-28 株式会社Lg化学 作为gpr120激动剂的联芳基衍生物
CN107108478B (zh) * 2014-12-29 2020-04-24 日本化学药品株式会社 Urat1抑制剂
CN108026043A (zh) * 2015-08-14 2018-05-11 广东东阳光药业有限公司 一种萘环化合物的晶型
CN105418495B (zh) * 2015-11-25 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 一种硫醚的制备方法
JP6752888B2 (ja) * 2015-12-07 2020-09-09 ヒノバ ファーマシューティカルズ インコーポレイテッド キノリン系化合物とその調製方法および尿酸トランスポータ阻害剤類薬物としての使用
CN108289848A (zh) * 2015-12-08 2018-07-17 阿迪亚生命科学公司 包含urat1的有效抑制剂的药物组合物
JP6898330B2 (ja) * 2015-12-28 2021-07-07 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド インドリジン誘導体、組成物、及び使用方法
WO2017121308A1 (fr) * 2016-01-11 2017-07-20 Chongqing Fochon Pharmaceutical Co., Ltd. Composés de pyrimidine fusionnés, compositions et procédés d'utilisation
EP3416955B1 (fr) * 2016-02-15 2020-09-09 Institut National de la Sante et de la Recherche Medicale (INSERM) Use of stiripentol and their derivatives for decreasing urinary oxalate concentration in an individual
CN105884807A (zh) * 2016-04-26 2016-08-24 昆药集团股份有限公司 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法
CN106117130A (zh) * 2016-06-28 2016-11-16 昆药集团股份有限公司 一种2‑((3‑(4‑氰基萘‑1‑基)吡啶‑4‑基)硫基)‑2‑甲基丙酸的晶型及其制备方法和药物组合物
CN106083847B (zh) * 2016-08-03 2018-10-30 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
CN110121359A (zh) 2016-11-11 2019-08-13 怀特黑德生物制剂研究所 人血浆培养基
CN106748987B (zh) * 2016-11-18 2019-05-31 昆药集团股份有限公司 2-((3-(4-氰基萘-1-基)吡啶-4-基)硫基)-2-甲基丙酸钠盐的晶型
BR112019011211A2 (pt) 2016-12-16 2019-10-15 Basf Se compostos de fórmula i, composição, métodos para combater ou controlar pragas invertebradas, para proteger plantas em crescimento de ataque ou infestação por pragas invertebradas, semente, uso de um composto e método para tratar ou proteger um animal
CN106883169A (zh) * 2017-04-01 2017-06-23 浙江永宁药业股份有限公司 一种3‑(4‑氰基‑1‑萘基)‑4‑卤代吡啶的制备方法及其应用
WO2018202039A1 (fr) * 2017-05-03 2018-11-08 成都海创药业有限公司 Composé hétérocyclique et son procédé de préparation
AU2018345221A1 (en) * 2017-10-04 2020-05-07 Japan Tobacco Inc. Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof
CN107955029B (zh) * 2017-12-07 2020-08-11 成都美域高制药有限公司 一种雷西纳德的制备方法
CN108084153A (zh) * 2017-12-20 2018-05-29 广东赛烽医药科技有限公司 吡啶基硫代乙酸化合物、组合物及其应用
CN108069940B (zh) * 2017-12-20 2021-04-30 广东赛烽医药科技有限公司 硫代乙酸化合物、组合物及其应用
CN108440397B (zh) * 2018-03-06 2020-06-05 南方医科大学 3-(萘-1-甲基取代)吡啶衍生物及其合成方法和应用
WO2019183835A1 (fr) 2018-03-28 2019-10-03 Inventisbio Shanghai Ltd. Nouvelles formes salines d'inhibiteurs d'urat-1
CN109608432B (zh) * 2018-12-17 2022-10-11 江苏艾立康医药科技有限公司 作为urat1抑制剂的噻吩类衍生物
WO2021009197A1 (fr) 2019-07-16 2021-01-21 Astrazeneca Ab Compositions pharmaceutiques résistantes à la décharge de dose comprenant du vérinurad
CN114315715B (zh) * 2020-09-29 2024-02-20 杭州中美华东制药有限公司 一类urat1抑制剂及其制备方法与应用
CN114621136B (zh) * 2020-12-09 2023-11-07 江苏正大清江制药有限公司 吡啶巯乙酸类化合物及其制备方法、药学衍生物或配剂以及应用
CN115385854B (zh) * 2021-05-19 2024-04-09 江苏正大清江制药有限公司 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用
CN113979931B (zh) * 2021-10-08 2023-06-13 南方医科大学 一种吡啶3-胺衍生物及其制备方法和应用
CN114214361A (zh) * 2022-01-07 2022-03-22 中国农业科学院兰州兽医研究所 一种urat1人源化小鼠模型的构建方法及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE642046A (fr) * 1963-01-03
ES475100A1 (es) * 1977-11-21 1979-12-01 Hoechst Ag Un metodo para preparar acidos 1,2-benzisoxazoloxiaceticos
JPS6054310B2 (ja) 1979-02-21 1985-11-29 三井東圧化学株式会社 ピリダジン誘導体と農園芸用殺菌剤
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5051442A (en) 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
KR100221041B1 (ko) 1990-11-30 1999-09-15 야스이 쇼사꾸 2-아릴티아졸 유도체 및 그의 약제학적 조성물
JPH06234732A (ja) * 1992-09-10 1994-08-23 Banyu Pharmaceut Co Ltd 置換アセトアミド誘導体
CA2105617A1 (fr) 1992-09-10 1994-03-11 Yoshikazu Iwasawa Derives acetamide substitues
US5344651A (en) 1993-07-23 1994-09-06 The Procter & Gamble Company Cyproterone acetate thioacetate
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
WO1995029897A1 (fr) 1994-04-29 1995-11-09 G.D. Searle & Co. Procede d'utilisation d'inhibiteurs de (h+/k+)atpase comme agents antiviraux
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
ES2339738T3 (es) * 1999-01-22 2010-05-25 Elan Pharmaceuticals, Inc. Derivados de acilo los cuales tratan trastornos relacionados con vla-4.
GB0108339D0 (en) 2001-04-03 2001-05-23 Syngenta Participations Ag Organics compounds
WO2007050087A1 (fr) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. Acides N[S(4-aryltriazol-3-yl)α-mercaptoacétyl]-p-aminobenzoïques EN TANT QU'INHIBITEURS DE TRANSCRIPTASE INVERSE DE VIH
SG155246A1 (en) 2004-08-25 2009-09-30 Ardea Biosciences Inc S-TRIAZOLYL α-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
WO2006138118A2 (fr) 2005-06-15 2006-12-28 New York Blood Center Compositions antivirales comprenant des phenyl-furanes heterocycliques substitues et composes associes
US20070099970A1 (en) * 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
EP2001897A2 (fr) 2006-03-22 2008-12-17 Syndexa Pharmaceuticals Corporation Composés et méthodes pour traitement de troubles associés à un stress du réticulum endoplasmique
AU2007292816B2 (en) 2006-09-07 2011-11-17 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (fr) 2006-12-27 2008-07-02 sanofi-aventis Carboxamides hétérocycliques et leur utilisation pour la stimulation de l'expression de la NO synthase
ES2431815T3 (es) * 2007-04-11 2013-11-28 Kissei Pharmaceutical Co., Ltd. Derivado de (aza)indol y uso del mismo para fines médicos
TWI415840B (zh) * 2007-11-27 2013-11-21 Ardea Biosciences Inc 新穎化合物、組合物及使用方法
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
JP2012502050A (ja) 2008-09-04 2012-01-26 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及びそれを使用する方法。
WO2010048592A1 (fr) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprenant l'acide 4-(2-(5-bromo-4-(1- cyclopropylnaphtalén-4-yl)-4h-1,2,4-triazol-3-ylthio)acétamido-3- chlorobenzoïque et ses sels de qualité pharmaceutique
US20120122780A1 (en) 2009-05-20 2012-05-17 Ardea Biosciences Inc. Compounds, Compositions and Methods for Modulating Uric Acid Levels
WO2010135536A2 (fr) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Procédés pour moduler des taux d'acide urique
WO2011044140A1 (fr) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Dérivés de salicylate d'acide thioacétique substitué et leurs utilisations
CA2802692C (fr) * 2010-06-16 2016-01-05 Ardea Biosciences, Inc. Phenylthioacetates utiles en tant qu'agents uricosuriques
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
JP6025853B2 (ja) * 2011-11-03 2016-11-16 アルデア バイオサイエンシーズ インク． ３，４−二置換ピリジン化合物、その使用方法、および、該化合物を含む組成物

Also Published As

Publication number Publication date
EP3409661A1 (fr) 2018-12-05
GT201200339A (es) 2015-02-11
KR101608604B1 (ko) 2016-04-01
SMT201400055B (it) 2014-07-07
ME02302B (fr) 2016-06-20
CU24126B1 (es) 2015-08-27
EA022933B1 (ru) 2016-03-31
SI2975025T1 (en) 2018-08-31
JP6364515B2 (ja) 2018-07-25
PT2975025T (pt) 2018-06-18
US10919858B2 (en) 2021-02-16
ES2459146T3 (es) 2014-05-08
SI2585437T1 (sl) 2014-07-31
US20130202573A1 (en) 2013-08-08
PT2585437E (pt) 2014-04-29
TWI460173B (zh) 2014-11-11
HUE025962T2 (en) 2016-05-30
JP5551310B2 (ja) 2014-07-16
EP2585437A2 (fr) 2013-05-01
HN2012002664A (es) 2015-06-29
US20130281469A1 (en) 2013-10-24
DOP2012000314A (es) 2013-06-30
DK2975025T3 (en) 2018-06-25
SI2712861T1 (sl) 2016-03-31
AU2011268360B2 (en) 2013-10-10
ECSP12012353A (es) 2013-01-31
JP2018168174A (ja) 2018-11-01
JP2014237639A (ja) 2014-12-18
SMT201500260B (it) 2016-01-08
LT2975025T (lt) 2018-06-25
KR20140037292A (ko) 2014-03-26
EA201270803A1 (ru) 2013-05-30
US20210171466A1 (en) 2021-06-10
HUE040209T2 (hu) 2019-02-28
DK2712861T3 (en) 2015-10-26
US8629278B2 (en) 2014-01-14
CA2802535A1 (fr) 2011-12-22
WO2011159839A2 (fr) 2011-12-22
JP2017122108A (ja) 2017-07-13
TW201504214A (zh) 2015-02-01
AU2011268360A1 (en) 2013-01-10
SG10201702527TA (en) 2017-04-27
MY153039A (en) 2014-12-31
MX2012014863A (es) 2013-02-15
US20190185431A1 (en) 2019-06-20
AR081930A1 (es) 2012-10-31
PL2712861T3 (pl) 2016-02-29
JP5768166B2 (ja) 2015-08-26
CO6640311A2 (es) 2013-03-22
EP2712861B1 (fr) 2015-07-29
HRP20151105T1 (hr) 2016-01-01
BR112012032028A2 (pt) 2016-11-08
US20130203779A1 (en) 2013-08-08
CA2802535C (fr) 2014-08-12
SG186298A1 (en) 2013-01-30
EP2585437A4 (fr) 2013-07-03
BR112012032028B1 (pt) 2021-05-04
RS54375B1 (en) 2016-04-28
ES2673426T3 (es) 2018-06-21
US8541589B2 (en) 2013-09-24
CN103864677A (zh) 2014-06-18
KR101432950B1 (ko) 2014-08-21
RS53301B (en) 2014-08-29
TW201211018A (en) 2012-03-16
PT2712861E (pt) 2015-11-20
HRP20180829T1 (hr) 2018-07-27
JP2013528655A (ja) 2013-07-11
MX343583B (es) 2016-11-10
CU20120170A7 (es) 2013-05-31
CN103068801B (zh) 2014-05-14
PL2585437T3 (pl) 2014-07-31
EP2975025A1 (fr) 2016-01-20
PL2975025T3 (pl) 2018-09-28
IL223435A (en) 2015-01-29
JP2015199760A (ja) 2015-11-12
RS57363B1 (sr) 2018-08-31
EP2975025B1 (fr) 2018-04-04
CN103068801A (zh) 2013-04-24
KR20130051469A (ko) 2013-05-20
TR201808344T4 (tr) 2018-07-23
HRP20140391T1 (hr) 2014-06-06
ES2551114T3 (es) 2015-11-16
DK2585437T3 (da) 2014-05-05
CN103864677B (zh) 2016-05-18
CL2012003546A1 (es) 2013-04-12
EP2585437B1 (fr) 2014-02-12
CR20120649A (es) 2013-04-17
ME01830B (me) 2014-12-20
IL236039A0 (en) 2015-05-31
PE20131047A1 (es) 2013-10-04
HK1219102A1 (zh) 2017-03-24
US10266493B2 (en) 2019-04-23
UA107115C2 (uk) 2014-11-25
JP6112318B2 (ja) 2017-04-12
WO2011159839A3 (fr) 2012-04-19
EP3611167A1 (fr) 2020-02-19
ZA201209574B (en) 2014-05-28
EP2712861A1 (fr) 2014-04-02
CY1120337T1 (el) 2019-07-10
TWI501949B (zh) 2015-10-01

Similar Documents

Publication Publication Date Title
HRP20180829T1 (hr) Spojevi tioacetata, pripravci i postupci za uporabu
IL250824A0 (en) Certain amino-pyrimidines, their assemblies, and methods of using them
EP2536756A4 (fr) Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation
EP2584897A4 (fr) Compositions contenant du resvératrol et procédés d'utilisation
EP2582664A4 (fr) Phénylthioacétates, compositions et procédés d'application
EP2569425A4 (fr) Compositions d'endoribonucléases et leurs procédés d'utilisation
EP2675471A4 (fr) Compositions liées à la sérumalbumine humaine et procédés d'utilisation
ZA201209259B (en) Uses and compositions
EP2596112A4 (fr) Compositions d'acétylcystéine et méthodes d'utilisation correspondantes
IL225227A0 (en) Preparations including fulvestrant and methods of use
EP2588117A4 (fr) Compositions antiseptiques stables et procédés
EP2590971A4 (fr) Composés utiles en tant qu'agents antiviraux, compositions, et procédés d'utilisation
ZA201302952B (en) Fungicidal compositions and methods of use
HK1201451A1 (en) Compositions and methods
GB201018650D0 (en) Methods and compositions
EP2637501A4 (fr) Compositions fongicides et procédés d'utilisation
HK1160777A1 (en) Novel use of neohesperidoside
GB201010608D0 (en) Compounds, compositions and use
HU1000688D0 (en) Use of trifluoro-phal
GB201018651D0 (en) Methods and compositions
GB201010083D0 (en) Compositions and methods
GB201009767D0 (en) Compositions and methods
GB201019291D0 (en) Compositions and uses